• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

High-Titer Convalescent Plasma Increases Long-Term Survival for Patients with Severe COVID-19

November 16, 2022

Randomized controlled clinical trials have evaluated the safety and efficacy of COVID-19 convalescent plasma (CCP) and found high-titer CCP reduced the risk of hospitalization if used early in the course of disease.  However, little is known about the long-term effect of CCP.  Fifty hospitalized patients (74% male; median age 58.5 years) with severe COVID-19 in the CASPID randomized clinical trial were followed for a median time of 396 days; 16 received high-titer CCP, 14 received low-titer CCP, and 20 received standard care.  In addition, 113 CCP donors (52% male; median age 42.0 years) were followed for a median of 519 days.  The one-year survival of patients in the high-titer CCP study arm (n=16) was 91.5%, which was significantly higher than patients in the low-titer arm (n=14; 67.4% survival) and the control arm (n=20; 60.2% survival).  Furthermore, patients treated with the high-titer CCP had a significantly shorter stay in the ICU and hospital compared to patients in the low-titer and control groups. The study also found that hospitalized patients with severe COVID-19 had a lower quality of life compared to CCP donors.  Larger studies are needed to confirm this observation and the long-term benefits of CCP.

Reference:

Körper S, Grüner B, Zickler D, Wiesmann T, et al.  One-year follow-up of the CASPID randomized trial for high-dose convalescent plasma in severe COVID-19 patients.  Journal of Clinical Investigation 2022

Filed Under

  • Coagulation & Plasma Transfusion
  • News

Recommended

  • Luspatercept versus Epoetin Alfa for Lower-Risk Myelodysplastic Syndrome

  • mRNA-1273 Vaccine Safe and Induces anti-SARS-CoV-2 Immune Responses

  • Evaluation of PrEP/PEP Deferrals and U.S. House of Representatives Question MSM Deferral Policy for Blood Donors

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

  • Distinct Roles for Differently Aged Platelets

  • Anemia Treatment Bundle Improves Hemoglobin Recovery after Critical Illness

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley